BioNTech SE is currently sponsoring a Phase II clinical study titled A Phase II, Multisite, Open-label, Single Arm Trial of BNT327 in Combination With Docetaxel in Second-line Stage IV Non-small Cell ...

TORONTO, Aug. 22, 2025 /CNW/ - With thousands of press releases published each week, it can be difficult to keep up with ...

The payoff in lives and hospital time saved runs at about 100 to 1 per dollar invested, which is a great deal by any standard ...

New data from the Kentucky Cabinet for Health and Family Services shows cases of the virus have jumped significantly in the ...

The immune system’s role is usually seen as wiping out invading pathogens like bacteria and viruses, but several types of ...

Since COVID, there've been growing initiatives in Africa to start producing vaccines and medicines locally, thus gaining greater independence from global supply chains. But are these schemes ...

The Emeryville, California-based biotech has just released topline results from a phase 1/2 head-to-head study comparing its ...

Kennedy Jr., a vaccine sceptic, announced Aug. 5 that his agency will cancel nearly $500 million in funding for mRNA ...

“This usual chain of decisions … has been disrupted. And without clarity and coordination, millions may not be able to have ...

As a summer COVID-19 surge hits Michigan, unanswered questions abound about eligibility, insurance coverage and when new ...

Biosimilar Market was estimated at USD 31.20 Bn in 2024 and is expected to grow at a CAGR of 17.4% from 2025 to 2032, reaching nearly USD 112.59 Bn by 2032. Biosimilars are redefining access to ...